嵌合H3亚型流感减毒活疫苗可诱导针对甲型流感病毒的广谱免疫应答
研究以A/列宁格勒/134/17/57(H2N2)骨架构建表达嵌合H3血凝素的减毒活疫苗,在小鼠中经鼻内初免-加强免疫后诱导了细胞免疫、交叉反应性IgA和广谱血清抗体,同源亚型攻毒完全保护,异亚型攻毒部分保护。
要点
- 嵌合H3减毒活疫苗在小鼠中呈温度敏感和冷适应表型,未引起明显体重下降或临床体征。
- 免疫后脾和肺IFN-γ+、IL-4+ T细胞频率增加,肺组织驻留记忆T细胞和交叉反应性IgA升高。
- 同源H3N2攻毒完全保护,H1N1异亚型攻毒存活率分别为20%和40%,传统单价苗组均为0%。
核心结论
- 嵌合抗原与减毒活疫苗结合可诱导多层免疫应答,为应对H3N2病毒快速抗原演化提供了合理的疫苗设计策略。
研究设计与样本
- 以A/列宁格勒/134/17/57(H2N2)为骨架构建表达嵌合H3血凝素的重配减毒活疫苗,在BALB/c小鼠中经鼻内初免-加强免疫并攻毒。
主要发现
- 重配病毒呈温度敏感和冷适应表型,小鼠未出现明显体重下降或临床体征。
- 免疫后脾和肺IFN-γ+及IL-4+ T细胞频率增加,肺组织驻留记忆T细胞水平升高。
- 鼻和支气管肺泡灌洗液中检测到高水平交叉反应性IgA,覆盖多个流感病毒株。
- 血清HI和MN抗体分别针对9株H3N2疫苗株中的8株和7株。
- 同源H3N2攻毒完全保护,异亚型H1N1攻毒存活率分别为20%和40%,传统单价减毒活疫苗或灭活疫苗组均为0%存活。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Influenza A(H3N2) viruses are typically associated with reduced vaccine effectiveness (VE), especially in the elderly. To address this challenge, we developed a novel live attenuated influenza vaccine (LAIV) expressing a mosaic H3 hemagglutinin designed to maximize potential cytotoxic T lymphocyte (CTL) epitope coverage, using the A/Leningrad/134/17/57 (H2N2) backbone. The resulting mosaic reassortant virus exhibited temperature-sensitive and cold-adapted phenotypes and caused no significant weight loss or clinical signs in mice. Following prime-boost intranasal immunization in BALB/c mice, robust cellular immune responses were observed, with increased frequencies of splenic and pulmonary IFN-γ+ and IL-4+ T cells after restimulation, as well as elevated levels of pulmonary tissue-resident memory T cells. High levels of cross-reactive IgA were also detected in nasal and bronchoalveolar lavage fluids, covering multiple influenza virus strains. Additionally, broad serum antibody responses were induced, with HI and MN antibodies targeting 8 and 7 of 9 H3N2 vaccine strains. Virus challenge results showed that the mosaic reassortant virus conferred complete protection against the homologous-subtype strain A/Aichi/2/1968 (H3N2) and partial protection against the heterosubtypic strains A/Puerto Rico/8/1934 (H1N1) and A/Hunan/42443/2015 (H1N1), with survival rates of 20 % and 40 %, respectively. In contrast, all mice vaccinated with traditional monovalent LAIV or inactivated influenza vaccine showed 0 % survival. Moreover, lung viral loads showed a decreasing trend after infection, and pathological damage in the lungs was markedly alleviated compared to other groups. These findings suggest that combining the mosaic antigen with LAIV induces multi-layered immune responses and provides a rational vaccine design strategy for addressing the rapid antigenic evolution of H3N2 viruses.
引用
- Yang Z, Zhang S, Zhao Y, et al. A mosaic H3 subtype live attenuated influenza vaccine elicits broad immune responses to influenza a viruses. Vaccine. 2025. PMID: 40997376. doi:10.1016/j.vaccine.2025.127776
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。